WAM
LAB icon

Wealthspire Advisors (Maryland)’s Standard BioTools LAB Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,069
Closed -$6K – 2509
2018
Q1 		$6K Sell
1,069
-496
-32% -$3.26K ﹤0.01% 1742
2017
Q4 		$9K Sell
1,565
-299
-16% -$1.64K ﹤0.01% 1631
2017
Q3 		$9K Buy
1,864
+1,102
+145% +$4.63K ﹤0.01% 1615
2017
Q2 		$3K Hold
762
– – ﹤0.01% 1896
2017
Q1 		$4K Buy
+762
New +$4.83K ﹤0.01% 1566
2016
Q2 		– Sell
-100
Closed -$1K – 1760
2016
Q1 		$1K Buy
+100
New +$721 ﹤0.01% 1653

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s LAB Position: Q2 2018 in Review

Wealthspire Advisors (Maryland) sold out of Standard BioTools (LAB) in Q2 2018, closing a stake of 1,069 shares — an estimated $6K sold.

Wealthspire Advisors (Maryland) first reported a position in LAB in Q1 2016 and held it in 6 quarters. The position peaked at $9K in Q4 2017. 84 funds tracked by Wall St. Rank hold LAB as of Q2 2018.

  • Wealthspire Advisors (Maryland) reported no remaining Standard BioTools position as of Q2 2018 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 1,069 Standard BioTools shares in Q2 2018, an estimated $6K.
  • Wealthspire Advisors (Maryland) first reported a position in Standard BioTools in Q1 2016 and held it in 6 quarters.
  • Wealthspire Advisors (Maryland)'s Standard BioTools position peaked at $9K in Q4 2017.
  • 84 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2018.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2018, filed 8 Aug 2018.